The relationship of molecular-genetic markers of chemokines with clinical manifestations of chronic kidney disease by Nekipelova, E. V. et al.
Helix Vol. 8(1): 2581- 2583 
2581 Copyright © 2018 Helix ISSN 2319 – 5592 (Online) 
 
 
The Relationship of Molecular-Genetic Markers of Chemokines with 
Clinical Manifestations of Chronic Kidney Disease 
*1Elena V. Nekipelova, 2Olga N. Novakova, 3Tatyana I. Yakunchenko, 4Mikhail I. Churnosov, 
 5Nina I. Zhernakova, 6Vladimir F. Kulikovskiy 
1, 2, 3, 4, 5, 6 Belgorod State University, 85 Pobedy Street, Belgorod, 308015, Russia 
*Email: litovkina@bsu.edu.ru 
 
Received: 21st October 2017 Accepted: 16th November 2017, Published: 31st December 2017 
 
Abstract 
The article presents the results of studying the 
relationship of polymorphic variants of chemokine 
genes (1931A/T CCL4, A/G CXCL11 (rs4512021), -
403A/G CCL5, C/G CCL2 (rs2857657), -801G/A 
CXCL12) with the features of clinical manifestations 
of chronic glomerulonephritis. It was revealed, that 
the allele-801 A CXCL12 (OR = 1.85, p = 0.04) was 
the marker for the development of hematuric form of 
chronic glomerulonephritis. 
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Introduction 
Chronic glomerulonephritis (CGN) is one of the most 
common chronic kidney diseases, which come to 
death of patients, due to the development of renal 
failure (Wada et al., 2008; Litovkina et al., 2014). 
Despite the relatively low prevalence of CGN in 
population, the progressive course of disease is the 
reason why patients with chronic glomerulonephritis 
are the main contingent of nephrology departments, 
hemodialysis and kidney transplantation (Nekipelova 
et al., 2016). The progression of nephritis and the 
development of renal failure depend on the activity of 
the process, which is not always clinically evident. 
Due to this, CGN is often diagnosed for the first time 
at the terminal stage of chronic kidney disease. 
Platelets and neutrophils play a major role among the 
cellular mediators of immune destruction of the 
glomerular renal apparatus, including CGN 
(Woerkom et al., 2000). Their number in leukocyte 
infiltration depends on the concentration of tumor 
necrosis factors, interleukins and chemokines, which 
induce respiratory explosion of neutrophilic 
granulocytes. It should also be noted, that among the 
cytokines, chemokines occupy a special place in the 
development of immune-inflammatory reactions in 
case of chronic glomerulonephritis. They are 
produced by immunocompetent cells, infiltrating the 
glomerular zone and the interstitial space of damaged 
nephrons (Wada, 2008; Azmandian et al., 2012). 
According to the literature data, such chemokines as 
monocyte chemotactic protein-1 (CCL2) and CCL5-
factor, regulating the activation of normal T-cell 
expression and secretion, play an important role in 
the pathogenesis of CGN (Lin et al., 2009). 
Therefore, further investigations, aimed at studying 
the mechanisms of emergence, development and 
progression of chronic glomerulonephritis, remain an 
important task for both modern nephrology and 
medicine in general. The aim of our work is to study 
the relationship between polymorphic variants of 
chemokine genes (+1931А/Т ССL4, A/G CXCL11 
(rs4512021), -403A/G CCL5, C/G CCL2 
(rs2857657), -801G/A CXCL12) and the features of 
clinical manifestations of chronic glomerulonephritis, 
namely with various clinical forms of the disease. 
 
Materials and Methods 
Two samples were formed for the research. The 
control group included 462 people, the group of 
patients with chronic glomerulonephritis consisted of 
238 individuals. The samples of patients and control 
group included Russian residents of the Central 
Chernozem Region of Russia, who do not have any 
kinship. Patients were included to the corresponding 
group after diagnosis of the disease, confirmed by 
clinical and laboratory-instrumental methods of 
examination, on the basis of Nephrology Department 
of the Belgorod Regional Clinical Hospital. Patients 
with hypertension and diabetes (in past medical 
history or identified during the examination) were 
excluded from the group of patients. All patients 
signed an informed consent for inclusion in the 
research and the use of obtained data. The control 
group consisted of individuals without kidney disease 
and hypertension. 
Venous blood, in the volume of 8-9 ml, taken from 
the ulnar vein of proband, was used as a material for 
the study. The recovering of genomic DNA from 
peripheral blood was carried out by a standard 
phenol-chloroform extraction method (Miller et al., 
1988). The analysis of the studied loci was carried 
out by the method of polymerase chain reaction of 
DNA synthesis, using oligonucleotide primers and 
probes. 
Statistical processing of data was carried out using 
the software packages "STATISTICA for Windows 
8.0" and "Microsoft Excel 2007". The criterion 2 
was used for the analysis of correspondence between 
the observed and expected distributions of genotypes, 
on the basis of Hardy-Weinberg equilibrium. The 
analysis of association of alleles and genotypes of the 
studied DNA markers, with various clinical forms of 
chronic glomerulonephritis, was carried out using 
conjugation tables 2x2, with the calculation of the 
criterion 2, with the Yates correction for continuity 
and odds ratio (OR) with 95% confidence intervals 
(CI). 
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Result and Discussion 
238 patients with chronic glomerulonephritis and 462 
persons from the control group were examined. The 
control group is fully comparable with the sample of 
CGN patients by age, nationality and place of birth. 
Genotyping of five polymorphic markers of 
chemokine genes was carried out: (+1931А/Т ССL4, 
A/G CXCL11 (rs4512021), -403A/G CCL5, C/G 
CCL2 (rs2857657), -801G/A CXCL12). Inclusion in 
the analysis of the above genetic polymorphisms was 
due to the pathogenetic significance of determined 
chemokines for CGN (Anders et al., 2010). 
The investigation of the allele frequencies of studied 
polymorphic markers of genes revealed, that the 
empirical distribution of genotypes corresponds to the 
theoretically expected, at Hardy-Weinberg 
equilibrium (p> 0.05), for all studied loci in the group 
of CGN patients, and in the control group (Table 1). 
 
Table 1. 
Summary Information about the Studied 
Polymorphisms 
Polymorphism 
Studied 
groups 
Minor allele MAF (%) 
HWE 
χ2 p 
+1931А/Т ССL4 
+1931А/Т ССL4 
A/G CXCL11 
A/G CXCL11 
-403A/G CCL5 
-403A/G CCL5 
C/G CCL2  
C/G CCL2  
-801G/A CXCL12 
-801G/A CXCL12 
Case 
Control 
Case 
Control 
Case 
Control 
Case 
Control 
Case 
Control 
+1931TССL4 
+1931TССL4 
GCXCL11  
GCXCL11 
-403ACCL5 
-403ACCL5 
G CCL2  
G CCL2  
-801A CXCL12 
-801A CXCL12 
27.78 
27.27 
39.07 
43.96 
17.12 
17.88 
18.86 
15.56 
17.04 
17.14 
1.24 
0.36 
0.10 
0.10 
0.52 
0.04 
0.67 
0.10 
0.46 
0.23 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
Notes: MAF, minor allele frequency; HWE, Hardy–
Weinberg equilibrium. P values were calculated 
using the χ2 test. 
 
At the next stage of our work, the study of the 
relationship between molecular genetic markers and 
the clinical features of CGN, characterizing the 
course of the disease, was carried out. The analysis of 
clinical forms in patients with CGN shows, that the 
disease is manifested in a mixed form (23.3%), 
nephrotic form occurs in 22.7% of patients, latent and 
hypertonic forms of chronic glomerulonephritis are 
observed in 19% of patients (each form) and 16% of 
individuals have a hematological form of CGN. 
The comparative study of genotypes frequencies of 
the studied polymorphic markers of chemokines 
showed, that patients with hypertensive form of CGN 
had higher concentration of the genotype -403 GА 
CCL5 (49.50%), in comparison with the control 
group (29.65%, OR = 2.15, 95% CI 1.06-4.33, χ 2 = 
4.63, p = 0.03). At the same time, the highest 
frequency of genotype GG CCL2 (rs 2857657) was 
revealed in patients with nephrotic CGN (9.53%),as 
in comparison with the population control (2.22%, 
OR = 4.42, 95% CI 1.11-16.36, 2 = 4.61, p = 0.03), 
as compared to the patients with other clinical forms 
of CGN (0-5.67%). However, it should be noted, that 
these genetic differences of individuals with 
hypertonic and nephrotic forms of CGN, in case of 
introduction the Bonferroni correction (it is the 
correction, minimizing the errors of the first kind, i.e. 
errors, connected with the obtaining of false positive 
results) do not reach a statistically significant level 
(рcor = 0.09). 
According to the literature sources, it is known, that 
in the pathogenesis of CGN, a special place belongs 
to such chemokines as CCL5 and CCL2 (Peterson et 
al., 2004; Stasikowska et al., 2007). CCL2, activating 
the tubular cells, causes an increase in the secretion 
of some pro-inflammatory cytokines, for example 
interleukin-6. Chemokines are involved in the 
activation of endothelial cells - they stimulate the 
synthesis of integrins (ICAM-1) on their surfaces, 
and provide strong adhesion and transmigration of 
leukocytes through the endothelium, during the 
formation of infiltrate (Zarbock et al., 2007). Under 
the influence of CCL2, there is also the proliferation 
of smooth muscle cells of the vessels, with the 
secretion of proinflammatory cytokines by them, 
promoting the progression of kidney disease, due to 
vascular damage. 
CCL5 is an integral modulator of many 
immunological, allergic and inflammatory reactions. 
It participates in the migration and accumulation of 
lymphocytes, monocytes and eosinophilic 
granulocytes in inflammatory foci and pathologically 
damaged areas of tissues and organs; it is a mediator 
of angiogenesis (Mehrad et al., 2007). This 
chemokine increases the number of macrophages and 
T-lymphocytes in damaged kidney structures, which 
secrete a spectrum of pro-inflammatory cytokines, 
causing the destruction of tubular cells and 
surrounding connective tissue elements, leading to 
sclerosis of glomeruli and fibrosis of interstitial tissue 
(Muro et al., 2008). Significant changes in the level 
of CCL5 in peripheral blood, in case of chronic 
glomerulonephritis, have been described (Nomura et 
al., 2007). 
The study of the distribution of alleles of 
polymorphic chemokine loci among patients with 
different clinical forms of CGN revealed the 
following features. In patients with a hematuric form 
of chronic glomerulonephritis, the prevalence of 
allele -801 A CXCL12 is 27.78%, that is 1.6 times 
higher than in the control group (17.14%, OR = 1.85 
95% CI 1.04-3.30, 2 = 4.44, p = 0.04). Attention is 
drawn to the fact of significant increase in the 
concentration of this allele in patients with hematuric 
form of CGN (27.78%), compared to patients with 
other clinical forms of disease (11.90-18.75%). 
It should be noted, that in the available literature 
sources there is no information about the 
interrelationships of the locus-801G/A CXCL12 with 
chronic glomerulonephritis. As a stimulator of B-cell 
precursors growth, CXCL12causes the increase in the 
homing of certain types of stem cells to damaged 
organs (including kidneys), the stimulation of 
proliferation, increased adhesion and cell mobility in 
the pathological focus (Karimabad et al., 2015); that 
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is important in the development of immune-
inflammatory reactions in the glomerular apparatus of 
kidneys (Graham, 2009). 
 
Conclusion 
Thus, within the framework of the present work, the 
study of the associations of chemokines polymorphic 
genetic markers with the features of clinical 
manifestation of chronic glomerulonephritis was 
carried out. It was established, that the allele-801 A 
CXCL12 (OR = 1.85) could be considered as a 
marker for the development of hematuric form in 
patients with chronic glomerulonephritis. 
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